Css LLC Il Raises Stake in Bristol-Myers Squibb (NYSE:BMY)

Css LLC Il lifted its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 19.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 31,940 shares of the biopharmaceutical company's stock after purchasing an additional 5,310 shares during the quarter. Css LLC Il's holdings in Bristol-Myers Squibb were worth $1,807,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Fairway Wealth LLC purchased a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at approximately $28,000. Transce3nd LLC purchased a new stake in Bristol-Myers Squibb in the fourth quarter valued at $28,000. Comprehensive Financial Planning Inc. PA acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at $34,000. Tacita Capital Inc acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth about $39,000. Finally, M Holdings Securities Inc. acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth about $39,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on BMY shares. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $55.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. Jefferies Financial Group dropped their target price on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a report on Wednesday, April 23rd. UBS Group decreased their price target on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research note on Friday, April 11th. Citigroup lifted their price objective on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a research note on Tuesday, January 28th. Finally, The Goldman Sachs Group reissued a "neutral" rating and set a $55.00 target price (down previously from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, Bristol-Myers Squibb presently has an average rating of "Hold" and an average target price of $58.00.

Bristol-Myers Squibb Stock Performance

Shares of BMY stock opened at $47.84 on Wednesday. The company has a market cap of $97.36 billion, a P/E ratio of -10.82, a PEG ratio of 2.07 and a beta of 0.39. The firm has a fifty day moving average price of $52.55 and a 200 day moving average price of $55.89. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The business had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. During the same period in the prior year, the firm posted ($4.40) EPS. The business's quarterly revenue was down 5.6% compared to the same quarter last year. Sell-side analysts predict that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Friday, April 4th were issued a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 5.18%. The ex-dividend date of this dividend was Friday, April 4th. Bristol-Myers Squibb's payout ratio is 92.88%.

Insider Activity at Bristol-Myers Squibb

In related news, EVP Samit Hirawat acquired 4,250 shares of the firm's stock in a transaction on Friday, April 25th. The stock was bought at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the purchase, the executive vice president now directly owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.07% of the company's stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.